Skip to main content

Prostate cancer: profiling and evaluation of ncRNA

Objectif

Annually, over 200 000 new prostate cancer cases are diagnosed in Europe. This number is expected to further increase due to widespread use of prostate specific antigen (PSA) tests on asymptomatic men and an aging population. This leads to high rate of over-detection, where most cases will never experience cancer symptoms during their lifetime. Hence, our current lack of means to predict prostate cancer prognosis will have devastating impact on both life-quality and health care expenditures. Molecular mechanisms of the development of prostate cancer are largely unknown apart from the recognized role of androgens. Lack of knowledge on mechanisms leading to the development and progression of this cancer hampers development of efficacious prevention, specific diagnostics, prognostic, and therapeutic tools. Based on the emerging knowledge on the function of non-coding RNAs (ncRNAs) as regulators of key cellular mechanisms and our own preliminary data on expression of ncRNAs in prostate cancer, it is very likely that ncRNAs are involved in the tumorigenesis and progression of prostate cancer. Our planned studies of ncRNAs can contribute major breakthroughs to optimize individualized prostate cancer treatment by providing both novel biomarkers and drug targets. In this project, we will pursue two major clinical problems: 1) early identification of cases requiring aggressive curative treatment, and 2) develop efficient therapies against hormone-refractory prostate cancer. The project will cover all phases of translational research, from discovery to validation and implementation. We will identify novel ncRNAs, investigate their expression, genetic/epigenetic alterations, and function. We will develop diagnostic tools, identify and validate therapeutic targets. To assure the success of the project, our consortium consists of leading translational prostate cancer research centers in Europe and companies committed to develop ncRNA detection technologies and novel drugs.

Appel à propositions

FP7-HEALTH-2007-A
Voir d’autres projets de cet appel

Coordinateur

TAMPEREEN YLIOPISTO
Adresse
Kalevantie 4
33014 Tampere
Finlande

Voir sur la carte

Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Hannele Auffermann (Ms.)
Contribution de l’UE
€ 639 568

Participants (7)

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Pays-Bas
Contribution de l’UE
€ 452 520
Adresse
Dr Molewaterplein 40
3015 GD Rotterdam

Voir sur la carte

Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Nuran Tuzen (Ms.)
THE UNIVERSITY OF SHEFFIELD
United Kingdom
Contribution de l’UE
€ 371 296
Adresse
Firth Court Western Bank
S10 2TN Sheffield

Voir sur la carte

Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Joanne Watson (Ms.)
LUNDS UNIVERSITET
Suède
Contribution de l’UE
€ 448 680
Adresse
Paradisgatan 5c
22100 Lund

Voir sur la carte

Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Kristian Riesbeck (Prof.)
EXIQON AS
Danemark
Contribution de l’UE
€ 449 400
Adresse
Bygstubben 9
2950 Vedbaek

Voir sur la carte

Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contact administratif
Søren Echwald (Dr.)
ORION OYJ
Finlande
Contribution de l’UE
€ 93 000
Adresse
Orionintie 1
02200 Espoo

Voir sur la carte

Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contact administratif
Ville Hassinen (Mr.)
TURUN YLIOPISTO
Finlande
Contribution de l’UE
€ 451 752
Adresse
Yliopistonmaki
20014 Turku

Voir sur la carte

Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Eliisa Särkilahti (Dr.)
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
Contribution de l’UE
€ 80 000
Adresse
Wellington Square University Offices
OX1 2JD Oxford

Voir sur la carte

Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Linda Polik (Ms.)